Ongoing Clinical Trials for Vulvovaginal Pruritus
Currently, there is 1 ongoing clinical trial investigating treatments for vulvovaginal pruritus and related conditions in postmenopausal women. This trial is examining the effects of vaginal estrogen therapy on blood clotting parameters in women experiencing vaginal atrophy symptoms.
Clinical trial locations
Study on the Effects of Vaginal Estrogen Treatment with Nomegestrol Acetate and Estradiol Hemihydrate on Blood Clotting in Postmenopausal Women with Vaginal Atrophy
This clinical trial is being conducted in Denmark and focuses on understanding how local vaginal estrogen treatment affects blood clotting in postmenopausal women experiencing vaginal atrophy. The condition often causes uncomfortable symptoms including dryness, irritation, and discomfort in the vaginal area.
Main inclusion criteria: The trial is recruiting postmenopausal women who are 50 years of age or older. To qualify, participants must have been without menstrual periods for at least 12 months and must be experiencing symptoms of vulvovaginal atrophy, such as vaginal dryness, irritation, or discomfort. Women who have a medical need for standard treatment with vaginal estrogen (10 micrograms at least three times a week) are eligible. The trial accepts participants regardless of whether they have a history of venous thromboembolism, which is a condition where blood clots form in the veins.
Main exclusion criteria: Women who are not postmenopausal cannot participate. Men are excluded from the study. Additionally, people who belong to vulnerable populations, such as children, pregnant women, or individuals who cannot make decisions for themselves, are not eligible to participate.
Focus and goal: The primary aim of this trial is to examine how vaginal estrogen treatment influences the balance between blood clotting and the breakdown of clots in the body, known as hemostatic balance. This is important because changes in this balance can affect the risk of developing blood clots. Researchers will monitor participants over a three-month period, observing changes in blood clotting parameters. The study also seeks to compare these effects between women with and without a history of venous thromboembolism.
Investigational drug: The treatment being tested uses vaginal estrogen, specifically a combination of nomegestrol acetate and estradiol hemihydrate. These substances are chemically similar to hormones naturally found in the body. The estrogen is applied directly to the vaginal area at a dosage of 10 micrograms, at least three times per week. This local application helps relieve symptoms of vaginal atrophy while researchers study its effects on blood clotting processes.
Summary
This single ongoing trial represents a focused effort to better understand the safety profile of vaginal estrogen therapy in postmenopausal women. Located in Denmark, the study addresses an important question about how this commonly used treatment affects blood clotting mechanisms. The trial is particularly notable for its inclusion of women both with and without a history of blood clots, which will provide valuable comparative data. For women experiencing vulvovaginal pruritus and related symptoms of vaginal atrophy, this research may help inform future treatment decisions and safety guidelines.